Compagnie Chargeurs Invest (CRI) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
10 Sep, 2026Executive summary
Q1 2025 revenue reached €187.8 million, up 5.6% reported and 2.8% like-for-like year-over-year, driven by strong performances in Museum Studio and Personal Goods.
Museum Studio posted 31.2% reported and 23.8% like-for-like growth, fueled by a record order book and major project execution.
Novacel confirmed its rebound with 2.6% reported and 2.1% like-for-like revenue growth, supported by innovation and a positive product mix.
Personal Goods grew 21.4% reported and 20.0% like-for-like, reflecting robust brand momentum and retail expansion.
The group maintained confidence for 2025, emphasizing rigorous performance and cash management amid global uncertainties.
Financial highlights
Group revenue: €187.8 million in Q1 2025 vs. €177.8 million in Q1 2024 (+5.6% reported, +2.8% like-for-like).
Museum Studio revenue: €37.0 million (+31.2% reported, +23.8% like-for-like).
Novacel revenue: €74.3 million (+2.6% reported, +2.1% like-for-like).
Personal Goods revenue: €3.4 million (+21.4% reported, +20.0% like-for-like).
Chargeurs PCC revenue: €51.6 million (+0.6% reported, -4.8% like-for-like); Luxury Fibers: €21.5 million (-6.9% reported, -6.1% like-for-like).
Outlook and guidance
Management expressed confidence for the year, citing sectoral and geographic diversification and ongoing innovation.
Focus remains on tailored business development, performance discipline, and long-term value creation.
Latest events from Compagnie Chargeurs Invest
- Transformation to high-luxury focus, Novacel sale, and €14/share buyback drive strong outlook.CRI
Q2 2026 - Q1 2026 revenue fell, but strategic transformation accelerates with Novacel divestment and strong order books.CRI
Q1 2026 - Novacel sale and strategic refocus boost financial flexibility and target €1bn NAV by 2030.CRI
Q4 2025 - Strong Q3 growth in new businesses and luxury brands, with a robust outlook for 2026.CRI
Q3 2025 - Stable H1 2025 revenue and NAV growth, strong Museum Studio gains, Novacel disposal under review.CRI
Q2 2025 - Q3 2024 revenue up 11.2% year-over-year, led by Novacel and Museum Studio growth.CRI
Q3 2024 - Revenue up 11.1% and recurring operating profit up 33.9%, with strong cash flow and reduced net debt.CRI
Q2 2024 - Q1 2024 revenue up 10% as Chargeurs accelerates growth in high-value, sustainable markets.CRI
Investor Presentation - Strong growth, strategic transformation, and all resolutions passed amid market and regulatory risks.CRI
AGM 2025